Explained: The new drug for Alzheimers disease Explained News
Aducanumab’s (Aduhelm; Biogen) $56,000 price point reflects the larger challenges of the United States’ insurance system and incites a cyclical series of events that have repercussions on cost of future therapies, state budgets, and legislative decisions. The approval will bring massive financial gains for Biogen, which saw its shares gain 38 per cent after the…